CTRI/2021/02/031379尚未招募4 期
Denosumab for diabetic charcot neuroarthropathy in people with chronic kidney Disease:a randomized controlled study. - DECK
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- PGIMER
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Participants with any form of diabetes, age more than 18 years and with nephropathy defined as eGFR <60 ml/min/1.73 m2 (CKD-EPI equation) and /or presence of proteinuria defined as 24-hour urine albumin of 30-300 mg or macroalbuminuria 24-hour urine albumin of >300 mg and/or end stage kidney disease on maintenance dialysis or post renal transplant for DKD will be included.
排除标准
- •Patients with active foot ulcer or who have received denosumab or any other anti-resorptive therapy in the prior six months, harboring an active malignancy, pregnant or lactating women will be excluded from the study.
研究者
相似试验
已完成
2 期
ovel treatment of acute Charcot foot using the medication denosumab combined with immobilisation.Acute Charcot neuropathic osteoarthropathyMusculoskeletal - Other muscular and skeletal disordersMetabolic and Endocrine - DiabetesDiabetes mellitusACTRN12617000937314Garvan Institute of Medical Research26
已完成
3 期
Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot NeuroarthropathyCharcot Joint of FootNCT03174366Western University of Health Sciences7
招募中
3 期
The DENOCHARCOT TrialDiabetes MellitusCharcot FootNCT04547348Ole Lander Svendsen38
进行中（未招募）
1 期
Addition of Denosumab to two different neoadjuvant treatment schedules of nab-PaclitaxelEUCTR2015-001755-72-DEGerman Breast Group778
已完成
不适用
The effect of denosumab for the treatment of osteoporosis in hemodialysis patientsOsteoporosisJPRN-UMIN000014458Saiseikai Kumamoto Hospital40